REMARKS

As noted above, the amendments of the claims set forth above were made strictly to remove or decrease certain multiple dependencies, thereby reducing the total number of claims the extra claim fees.

It is respectfully submitted that the present claims are in condition for examination on the merits. However, if any questions remain, the Examiner or other PTO official is encouraged to call the undersigned at (202) 216-8584 to expedite this application.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 22-0261**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Date: July 27, 2001

Shmuel Livnat
Registration No. 33,949

VENABLE
P.O. Box 34385
Washington, D.C. 20043-9998
Telephone: (202) 962-4800
Telefax: (202) 962-8300

APPENDIX

AMENDED CLAIMS ONLY

(with markings to show changes)

6. *(amended)* The method of [any of] claim[s] 1[-5] wherein said outer surface protein capsid protein encoded by gene 10A or 10B of phage T7.

11. *(amended)* The method of [any of] claim[s] 1[-5], wherein said determining step (e) is performed by plating said eluted phage on a lawn of *E. coli*, permitting them to multiply and form plaques, and sequencing the DNA of the phages of any given plaque to obtain the sequence of the cDNA insert that encodes said PBD.

12. *(amended)* The method of [any of] claim[s] 1[-5], wherein said target epitopes are peptide epitopes and said family comprises peptides or polypeptides corresponding to (i) a protein fragment, (ii) a protein domain or (iii) a complete protein.

19. *(amended)* The method of [any of] claim[s] 1[-5], wherein said cDNA library is produced from mRNA molecules of said biological source by random priming wherein each cDNA molecule reverse transcribed from said mRNA molecules is between about 50 and about 5000 bp in length, the cDNA molecules are gel purified and directionally cloned into said T7 phage DNA resulting in fused DNA, and said fused DNA is packaged into phage *in vitro*.

23. *(amended)* A method to determine the representation of expressed sequences in a PBD display sublibrary, when said PBDs are from a known protein and specific antibodies for epitopes of the known protein are available,

(i) providing a collection of antibodies specific for the epitopes of the known protein which antibodies are immobilized to a solid support;

(ii) carrying out the method of claim 4 [5 or 6] up to an eluting step wherein the first sublibrary, the second sublibrary or a subsequent sublibrary is obtained;

(iii) contacting the sublibrary obtained in step (ii) with the antibodies of step (i) and permitting the antibodies to bind to the epitopes of the displayed PBDs

(iv) evaluating the results of the binding, thereby determining the representation of the expressed sequences in said sublibrary.

APPENDIX

26. *(amended)* The method of [any of] claim[s] 1[-5] wherein the biological source is selected from the group consisting of developing chick neural retina, cultured neonatal rat Schwann cells, and myelinating sciatic nerves of 15-25 day old rat.

29. *(amended)* The method of [any of] claim[s] 1[-5], wherein

(a) the phage display library displays PBDs of a protein selected from the group consisting of β-catenin, PTP1B, p120ctn and Shc; and

(b) the target epitopes are peptides of N-cadherin.

30. *(amended)* The method of [any of] claim[s] 1[-5], wherein

(a) the phage display library displays PBDs of synaptotagmin SytI and the target epitopes are peptides of synaptotagmin Syt IV; or

(b) the phage display library displays PBDs of SytIV and the target epitopes are peptides of Syt I.

31. *(amended)* The method of [any of] claim[s] 1[-5], wherein

(a) the phage display library displays PBDs of SytI or Syt IV and the target epitopes are peptides of syntaxin; or

(b) the phage display library displays PBDs of syntaxin and the target epitopes are peptides of Syt I or Syt IV.